EFA Technologies

EFA Technologies Overview

EFA Technologies is developing the RevDx, an affordable handheld blood test diagnostic tool. The RevDx is a mobile end-point solution for performing automatic microscopy tests, including whole blood sampling and an automatic diagnosis of blood count. The product is easy to operate and uses a blood sample from finger prick without the need for laboratory conditions or specific preparations, enabling users to make real-time informed decisions. The RevDx is a disease-mapping solution for integrated community case management. The real-time, multichannel platform is a programmable portable lab that aims to automatically diagnose infectious diseases, starting with parasitology and blood cell count, in order to enable safe, precise, and affordable testing, treating, and tracking.

Cumulative Funding Raised Over Time ($)

Latest News

Apr 9, 2024 · www.globenewswire.com

growth-positive

EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device

EFA Technologies, a pioneer in portable blood labs, has announced its entry into the Brazilian market with its flagship product, RevDx, following approval from Anvisa. The company also secured $6.5 million in funding from existing investors and new partners, including E-Health Ventures, Venturing Tech, ARC Impact Ventures, and the Israeli Innovation Authority. This funding will support product development, market expansion, and innovation in healthcare diagnostics. RevDx is a portable diagnostic device that offers rapid and accurate medical testing, revolutionizing on-site diagnostics. EFA Technologies aims to make Medtech accessible globally, starting with Brazil.

CustomersInvestmentExpand

Mar 20, 2019 · www.prnewswire.com

growth-positive

Merchavia Expands Its Investments in Diagnostics: The Company to Invest NIS 1 Million in EFA - Engineering for All Ltd.

Merchavia Holdings and Investments, an Israeli investment company, is expanding its investments into the diagnostics sector. They will invest NIS 1 million in EFA, a company developing a device for accurate mobile blood counts and treatment decisions. The device aims to make treatment for infectious diseases more effective, save lives and costs, and reduce excessive antibiotic use. EFAs system is designed for easy operation and suitable for use in various settings. The investment aligns with Merchavias strategy of focusing on breakthrough technologies in large markets. The global diagnostics market is estimated to be worth $38 billion in 2022. EFA operates in the eHealth Ventures incubator, with partners including the Israel Innovation Authority, Maccabi Health Services, Medison, Cleveland Clinic, and Amgen.

Investment

Dec 11, 2018 · en.globes.co.il

growth-positive

Digital diagnostic lab co EfA raises $900,000

Israeli digital health technological incubator eHealth Ventures has invested $900,000 in its 8th portfolio company, Engineering for All (EfA). EfA, managed by Yoel Ezra, is developing RevDx, a lab-on-hand system that can enable fully automated, on-the-spot diagnostics and real-time disease mapping. The company is currently working on a functional prototype of the device. eHealth Ventures CEO Talor Sax has expressed excitement about the potential of the device and the experience of the EfA team.

Investment

Dec 11, 2018 · www.prnewswire.com

growth-positive

eHealth Ventures Invests in "Engineering for All" - Disruptive Lab-on-a-Chip Diagnostic Device

eHealth Ventures has announced the acceptance of its 8th portfolio company, Engineering for All (EfA), which is developing a revolutionary Digital Diagnostic programable lab-on-hand system. eHealth Ventures has invested $900,000 in EfAs seed financing round. The system aims to provide fully automated, on-the-spot gold standard microscopy diagnostics and real-time disease mapping. It includes capabilities for complete blood count (CBC) and parasitology, diagnosis of infectious diseases, and affordable test-treat-track treatment. The company has won awards in Israel and presented with delegations in India and Taiwan. The goal is to address the lack of access to healthcare for a billion people and reduce misdiagnosis and overuse of antibiotics. eHealth Ventures sees the potential of RevDx as a game-changing solution.

Investment

Funding

Team Members

4

Employees: 11-50

Web & Social Links

Locations

HaYozma Street 6, Yokne'am Illit, Israel

4901 Hampden Lane, Bethesda, MD, USA

Photos & Videos

3 item(s)

EFA Technologies Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info